Children drinking non-cow milk little shorter than peers

Agencies
June 25, 2017

Jun 25: A new study suggests drinking non-cow milk- soy, almond or rice milks - is linked to shorter kids.cowmilk

The study, published in the American Journal of Clinical Nutrition, found that each daily cup of non-cow's milk consumed was associated with 0.4 centimeters (0.15 inches) lower height than average for a child's age.

"We found that children who are consuming non-cow's milk like rice, almond and soy milk tended to be a little bit shorter than children who consumed cow's milk," said Dr. Jonathon Maguire, the study's lead author and a pediatrician and researchers at St. Michael's Hospital in Toronto.

"For example, a 3-year-old child consuming three cups of non-cow's milk relative to cow's milk was on average 1.5 centimeters shorter."

That's over half an inch difference, which Maguire said is "not a tiny difference when you're 3 years old."

The study was a cross-section involving 5,034 healthy Canadian children ranging in age from two to six years old. The subjects were on average 38 months of age, with 51% being male, and were recruited from nine family and pediatric health-care practices from December 2008 to September 2015.

Of those participating, about five percent drank exclusively non-cow's milks, and about 84% drank only cow's milk; about eight percent drank both and about three precent drank neither.

Maguire said the most surprising finding was "that the amount children were shorter depended on how much they were consuming."

"It's not like if you're not consuming cow's milk, you're a little shorter," he said. "It's more like if you are consuming non-cow's milk, with each cup that a child consumes, that child on average appears to be a little bit smaller, a little shorter. That's a bit surprising."

Does it matter if a kid is half an inch shorter at the age of three? Does it correlate to height in adulthood?

"That's one remaining question. We don't know if the kids consuming non-cow's milk, maybe they catch up over time, or maybe they don't. Time's going to have to tell," he said.

"We do know in general as pediatricians that children who are on a certain percentile line in terms of height tend to stay on that line for the rest of their childhood and into adulthood."

The findings are sure to add fire to the ongoing debate about the benefits of cow's milk versus dairy alternatives.

Amy Joy Lanou, a professor of health and wellness at the University of North Carolina-Asheville who was not involved in the research, said she had several issues with the study, most notably why only milk consumption was considered.

"It's just odd to me why we wouldn't be looking at the overall diets of the children," Lanou said. "If they're making the claim that it's because it's the difference in the types of milk the kids are drinking, well, what else are they eating?"

Lanou, whose research has led her to believe that cow's milk is "not a necessary food," said she believes the study makes an improper leap by implying that taller means healthier.

"Taller children and heavier children are not necessarily healthier adults, or even healthier children," she said. "I think they're using height as a marker for health, and I'm not sure that's appropriate."

Connie Weaver, a professor of nutrition science at Purdue University who was also not involved in the study, said she found it interesting.

"This is the first study that I recall directly comparing cow milk with plant-based beverages for a physiological benefit," she wrote in an email. "We know that some of the plant beverages, almond especially, have lower protein contents so I have speculated that calcium absorption may be lower. This would suggest that cow's milk is superior."

However, she says, "A wrong message would be if people who do not consume cow's milk would decide to avoid the plant-based milks also."

The study suggests that one reason for the difference in height might be that plant-based milks do not stimulate insulin-like growth factor, or IGF, production as well as cow's milk does. Studies have found that adults with higher levels of certain IGFs have increased risks of reproductive cancers.

"Having less IGF may compromise height but that may lower risk of fracture -- and some cancers, too," Weaver said.

Overall, she would advise parents that "cow's milk may be the best option, but plant-based beverages provide many needed nutrients like protein, calcium, magnesium, potassium," which is far better than what most kids might prefer to drink.

Lanou would tell parents who are already giving plant-based milks to their children not to worry -- but to make sure their kids are getting enough protein from other sources throughout the day.

Maguire said he'd like to see soy, almond and rice milks more tightly regulated to bring the industry, in line with cow's milk.

"As a consumer and as a parent, you have to be pretty savvy when going to the grocery store to choose a non-cow's milk beverage that has similar nutritional value as cow's milk," he said. "Many of those beverages are marketed as being equivalent to cow's milk when they're not."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 4,2020

The World Health Organisation on Wednesday said that anti-malarial drug hydroxychloroquine (HCQ) will return to the solidarity trial for the potential treatment of coronavirus disease.

At a press conference in the WHO headquarters in Geneva, Director General Tedros Adhanom Ghebreyesus said: "On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol. The Executive Group received this recommendation and endorsed continuation of all arms of the solidarity trial, including hydroxychloroquine."

The world health body had temporarily suspended the usage of HCQ from the solidarity trial for coronavirus treatment on May 25 soon after a study published in one of the most reliable medical journals, which had suggested that the drug could cause more fatalities among COVID-19 patients.

However, the WHO chief said that the decision was taken as a precaution while the safety data was reviewed.

Ghebreyesus also said that the Data Safety and Monitoring Committee will continue to closely monitor the safety of all therapeutics being tested in the solidarity trial.

"So far, more than 3,500 patients have been recruited in 35 countries. WHO is committed to accelerating the development of effective therapeutics, vaccines and diagnostics as part of our commitment to serving the world with science, solutions and solidarity," he said.

Soon after HCQ was suspended from the trial, the Indian government had said that the antimalarial drug has been known for its benefits for a long time and its usage will be continued on the frontline workers, including police and healthcare professionals, as prophylaxis. The government had also said that studies were being conducted and the drug would be included in the clinical trial also for the treatment of coronavirus disease.

US President Donald Trump also had strongly advocated the use of HCQ and called it a "game-changer". He went to the extent of saying that he had taken the medicine.

Launched by WHO and partners, solidarity trial is an international clinical trial to find an effective treatment for COVID-19, including drugs to slow the progression of the disease or improve survival. The trial, which enrols patients from different countries, "will compare four treatment options against standard of care to assess their relative effectiveness against COVID-19", said WHO. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 14,2020

UN, Jul 14: There will be no return to the "old normal" for the foreseeable future as a result of the ongoing COVID-19 pandemic, and too many countries were still headed in the wrong direction, the chief of the World Health Organization (WHO) warned.

"The virus remains public enemy number one, but the actions of many governments and people do not reflect this," Xinhua news agency quoted WHO Director-General Tedros Adhanom Ghebreyesus at as saying a regular briefing on Monday.

He noted that mixed messages from leaders are undermining trust, which is the most critical ingredient of any response, while the only aim of the virus is to find people to infect.

Things are going to "get worse and worse and worse", he warned, unless governments communicate clearly with their citizens and roll out a comprehensive strategy focused on suppressing transmission and saving lives, while populations follow the basic public health principles of physical distancing, hand washing, wearing masks, coughing etiquette and staying home when sick.

COVID-19 has been gaining its momentum lately.

According to Tedros, Sunday saw a record of 230,000 cases reported to WHO, of which almost 80% were from just 10 countries and about half from just two countries.

"But it does not have to be this way," he said, asking every single leader, government and individual "to do their bit to break the chains of COVID-19 transmission and end the collective suffering".

To control the disease and get on with people's lives, Tedros said, three things are required. The first is to focus on reducing mortality and suppressing transmission; the second is to focus on an empowered, engaged community that takes individual behaviour measures in the interest of each other.

And the third is a strong government leadership and coordination of comprehensive strategies that are communicated clearly and consistently.

"We weren't prepared collectively, but we must use all the tools we have to bring this pandemic under control. And we need to do it right now," he added.

At the WHO briefing on Monday, health experts also said there was evidence to suggest that children under the age of 10 were only very mildly affected by Covid-19, while those over 10 seemed to suffer similar mild symptoms to young adults.

To what extent children can transmit the virus, while it appears to be low, remains unknown.

On Tuesday, the number of global coronavirus cases cross the 13 million mark, according to the Johns Hopkins University.

The total number of cases currently stood at 13,070,097, while the fatalities rose to 572,411, the University's Center for Systems Science and Engineering (CSSE) revealed in its latest update.

The US accounted for the world's highest number of infections and fatalities at 3,363,056 and 135,605, respectively, according to the CSSE.

Brazil came in the second place with 1,884,967 infections and 72,833 deaths.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 10,2020

Early treatment with the antiviral drug remdesivir has been found to reduce viral load and prevent lung disease in macaques infected with SARS-CoV-2 that causes COVID-19, according to a study.

The findings, published in the journal Nature on Tuesday, support the early use of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia.

Researchers from the National Institutes of Health in the US noted that remdesivir has broad antiviral activity and has been shown to be effective against infections with SARS-CoV and MERS-CoV in animal models.

The drug is being tested in human clinical trials for the treatment of COVID-19, they said.

Researcher Emmie de Wit and colleagues investigated the effects of remdesivir treatment in rhesus macaques, a recently established model of SARS-CoV-2 infection.

Two sets of six macaques were inoculated with SARS-CoV-2.

One group was treated with remdesivir 12 hours later -- close to the peak of virus reproduction in the lungs -- and these macaques received treatment every 24 hours until six days after inoculation.

In contrast to the control group, the researchers found that macaques that received remdesivir did not show signs of respiratory disease, and had reduced damage to the lungs.

Viral loads in the lower respiratory tract were also reduced in the treated animals; viral levels were around 100 times lower in the lower-respiratory tract of remdesivir-treated macaques 12 hours after the first dose, they said.

The researchers said that infectious virus could no longer be detected in the treatment group three days after initial infection, but was still detectable in four out of six control animals.

Despite this virus reduction in the lower respiratory tract, no reduction in virus shedding was observed, which indicates that clinical improvement may not equate to a lack of infectiousness, they said.

Dosing of remdesivir in the rhesus macaques is equivalent to that used in humans, the researchers noted.

They cautioned that it is difficult to directly translate the timing of treatment used in corresponding disease stages in humans, because rhesus macaques normally develop only mild disease.

However, researchers said the results indicate that remdesivir treatment of COVID-19 should be initiated as early as possible to achieve the maximum treatment effect.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.